BACKGROUND Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT
and placebo in patients with recent ACS and LDL-C of 50 to 125 mg/dl. We tested the pre-specified hypothesis in IMPROVE-IT that, in addition to reducing first events in patients after an ACS, combination therapy with ezetimibe plus simvastatin would also reduce total events compared with simvastatin alone.
METHODS
The study design and primary results of IMPROVE-IT have been published previously (3) (4) (5) (6) . Patients who were $50 years of age were eligible for inclusion if they were hospitalized for an ACS within the preceding 10 days, with either acute myocardial infarction (MI) with or without electrocardiographic ST-segment elevation, or high-risk unstable angina (UA). Eligible patients had an LDL-C concentration of $50 mg/dl (1.3 mM/l), with a maximum of 125 mg/dl This model included an exposure variable for duration of follow-up as this could vary by subject.
Incidence-rate ratio (RR) and corresponding 95% confidence intervals (CI) are reported from the negative binomial regression model. In addition, we performed a pre-specified analysis using the Wei, Lin, and Weissfeld (WLW) method (7), which is a marginal model and an extension of survival models based on the Cox proportional hazard; the first 4 events that could have occurred in a subject were evaluated in the model. An additional sensitivity analysis was performed using a Prentice, Williams, and Peterson (PWP) model (8), which is a conditional model and also an extension of survival models based on the Cox proportional hazard. An Andersen Gill model was also performed as a sensitivity analysis using up to the first 4 events in a subject.
Efficacy comparisons were performed according to the intention-to-treat principle. All tests were 2-sided with a p value <0.05 considered to be significant.
Analyses were performed using Stata/IC version 13.1 software (College Station, Texas) and SAS version 9.3 software (Cary, North Carolina).
RESULTS
The median length of follow-up was 6 years (25th, 75th percentiles: 4.3 and 7.1 years). Compared to patients with only 1 event, patients with multiple events had more comorbidities at study entry, including hypertension and diabetes; were more often on prior statin therapy; and more frequently had previously experienced MI, angina, and revascularization ( Table 1 Baseline characteristics among patients who experienced at least 1 event were similar for those randomized to ezetimibe/simvastatin compared to those randomized to placebo/simvastatin (Online Table 1 ).
EVENTS. During the course of the trial, a total of 9,545 PEP events occurred. Of these, 5,314 (56%) were first events, which were included in the primary IMPROVE-IT study analysis (3), and there were an additional 4,231 (44%) events that occurred after the first PEP event during the course of the trial, and were thus not included in the primary analysis. Overall, a similar proportion of first and additional events were stroke, UA, and CV death ( Figure 1 ). In contrast, there were proportionately fewer MIs (24.0% vs. 31.7%) and proportionately more revascularizations (58.4% vs.
43.8%) among the additional events compared to the distribution of first events. There were a total of 48 peri-percutaneous coronary intervention (PCI) MI events, of which only 4 were the first PEP event that occurred in a subject; no subject had more than 1 peri-PCI MI during the trial.
When we considered the total number of events of the 18,144 subjects, 70.7% (n ¼ 12,830) had no events, 16 .6% (n ¼ 3,017) had a single event, 7.3% (n ¼ 1,325) had 2 PEP events, and 5.4% (n ¼ 972) had 3 or more such events (Online Table 2 ). The maximum number of events experienced was 14 events each in 2 patients. there was a 13% reduction in the total number of MIs
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Overall, a similar proportion of first and additional events were stroke (7.8% vs. 5.0%, respectively), unstable angina (4.2% vs. 2.8%, respectively), and cardiovascular death (12.4% vs. 9.8%, respectively). There were proportionately fewer MIs (24.0% vs. 31.7%, respectively) and proportionately more revascularizations (58.4% vs. 43.8%, respectively) among the additional events than among the first events. CVD ¼ Total events were consistently lower in the ezetimibe/simvastatin group for the 3 pre-specified secondary endpoints, as well as for the exploratory endpoint of CV death, MI, or stroke. CHD ¼ coronary heart disease death; CV ¼ cardiovascular; other abbreviations as in Figure 1 . For every 100 patients treated for 10 years, 11 total primary endpoint events were prevented with ezetimibe plus simvastatin. Abbreviations as in Figure 1 .
event until the first event has occurred. Other novel methods for analyzing additional events including the win ratio (23) and weighted composite endpoints (24) . As demonstrated by Bakal et al. (25) , model selection can impact the results and conclusion of events analysis (25) . In the present analysis, the results from both the WLW (7), Andersen Gill, and PWP (8) Translated into a risk difference, for every 100 patients treated for 10 years, 11 total PEP events were prevented with ezetimibe plus simvastatin ( Figure 5 ).
As there were no differences in cardiovascular death or unstable angina, these 11 total events prevented were due to a reduction 
